secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001213900-26-026644
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex terminates $108.4M ATM sales agreement; announces enhanced Phase 2 dose-optimisation study
--------------------------------------------------------------------------------

- Mutually terminated Sales Agreement with Curvature Securities and A.G.P., effective March 11, 2026.
- Raised aggregate gross proceeds of ~$108.4M under the agreement prior to termination.
- Issued press release announcing enhanced Phase 2 dose-optimisation study (likely IHL-42X for OSA).
- Corporate presentation confirms cash position of ~$70M as of December 2025.
- Pipeline includes Phase 2/3 trials for OSA, GAD, and RA with positive data reported August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026026644/0001213900-26-026644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026026644/ea0278415-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-026644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer